The investigational use version of the test, which may be used for real-time processing of fresh specimens in ongoing prospective studies, is now available to gain earlier insights on treatment response in clinical studies. "We are pleased to collaborate with Foundation Medicine and support broader access to cutting-edge tools that enable precision medicine," says Natera's Chief Executive Officer, Steve Chapman. "This aligns with Natera's mission to make our personalized monitoring assay technology available to all patients and improve outcomes." This launch closely follows two publications demonstrating the clinical validity of FoundationOne Tracker's value in the TRM and molecular residual disease (MRD) settings, respectively.